Clinical Trial Search

Primary: Alpha-synuclein Levels From Nasal Swabs

Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale

Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003

Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale

Primary: Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison — 4.18; 3.27; 3.85; 3.76 peak voxel z-score

Primary: Distribution Volume Ratio — 2.65; 2.70; 2.96; 2.74 Distribution volume ratios — p=0.05

Primary: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Pain Intensity - Short Form 3a Score — 0.42 score on a scale

Primary: Number of Participants With Residue of Concern (Observational) — 6; 6; 3; 6 Participants

Primary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants

Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score

Primary: Mitochondrial Respiration Efficiency (as Measured by OCR). — 67.7167; 53.7000; 73.3358; 68.5789 picomole/minute — p=<0.01

Primary: Change in Resting State Beta Band Power Over Time — -0.28 regression beta coefficient — p=0.038

Primary: Change in fMRI — 11 Participants

Primary: Treatment-emergent Adverse Events (TEAEs) — 238 Participants

Primary: Total Number of Cases With at Least One Provider Response — 98; 58 cases

Primary: Change in Clinical Disease Severity (CDR) — -0.1; 0.0; 0.0; 0.0 score on a scale

Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84

Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)

Primary: Change in Neurocognitive Functioning — -0.94; -0.81; -1.03; -0.51 Global Neurocognitive Z-Score — p=0.05

Primary: Assessment of the Effectiveness of Two Months of Use of the Remedee Endorphin Band Medical Device in Improving Motor Disorders in Patients With Parkinson's Disease — 6…

Primary: Treatment-emergent Adverse Events (TEAEs) — 115; 119 Participants

Primary: AMDX-2011P Adverse Events Profile — 0; 1; 3 Treatment Emergent Adverse Events TEAEs

Primary: Number of Participants With Clinically Significant Changes in Standard Laboratory Tests — 0 Participants

Primary: Localizing Brain Regions That Generate Interictal Spikes — 52 Participants

Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468

Primary: Number of Participants With Occurrence of Seizure — 0; 1 Participants

Primary: Charcot Marie Tooth Neuropathy Score — 25.67; 20.22 scores on a scale

Primary: Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ — 90.6; 95.9 Points on a scale — p=0.008

Primary: Phenylalanine Level in the Brain as Determined by MR Spectroscopy and in Blood — 130; 137; 961 umol/L

Primary: Change in Percent of Expected Lung Force Vital Capacity — -1.25 % Expected Forced Vital Capacity